2019 International Congress

September 22-26, 2019. Nice, France.

View by Title View Sessions

View by Date

Monday, September 23, 2019

1:45pm-3:15pm: Exploring the effects of intrastriatal AAV5-miHTT therapy on MRS signal and mutant huntingtin levels in the Q175FDN mouse model of HD

B. Leavitt, A. Vallès, A. Stam, C. Brouwers, V. Fodale, A. Bresciani, A. Hill, A. Yung, B. Russell-Schulz, P. Kozlowski, A. Mackay, D. Ma, F. Beg, J. Higgins, S. van Deventer, M. Evers, P. Konstantinova (Vancouver, BC, Canada)

Huntington’s Disease · Agora 3 West, Level 3

1:45pm-3:15pm: Exploring the experience and challenges for PD STAT clinical trial participants: a qualitative study

T. North, J. Grose, V. Eyre, D. Webb, R. Chapman, A. Foggo, M. Webber, C. Carroll (Plymouth, United Kingdom)

Clinical Trials, Pharmacology and Treatment · Agora 3 West, Level 3

1:45pm-3:15pm: Expression profiles from CD14+ monocytes in PD patients with GBA mutations

G. Riboldi, E. Udine, E. Navarro, M. Parks, B. Henderson, K. Sharma, T. Sikder, M. Zhuang, J. Crary, S. Frucht, T. Raj (New York, NY, USA)

Genetics · Les Muses Terrace, Level 3

1:45pm-3:15pm: Factitious Disorder Imposed on Another mimicking a Dopamine Dysregulation Syndrome

DRC. Carneiro, MS. Sousa, ASM. Morgadinho, CJ. Januário (Coimbra, Portugal)

Psychiatric Manifestations · Les Muses Terrace, Level 3

1:45pm-3:15pm: Factors Influencing Decision-Making About End of Life Care in Patients With Parkinson’s Disease and Their Family Members

R. Bužgová, R. Kozáková, M. Bar, M. škutová, P. Ressner, P. Bártová (Ostrava, Czech Republic)

Other · Agora 2 West, Level 2

1:45pm-3:15pm: Factors that interfere in the functionality according to Functional Independence Measure in people with Parkinson’s Disease.

E. Libardi, M. Piemonte, E. Guelfi, E. Okamoto (São Paulo, Brazil)

Physical and Occupational Therapy · Les Muses Terrace, Level 3

1:45pm-3:15pm: Factors underlying reduced aerobic capacity in Huntington disease

A. Rao, S. Norris, J. Montes, P. Wasserman, K. Marder (New York, NY, USA)

Huntington’s Disease · Agora 3 West, Level 3

1:45pm-3:15pm: Familial Creutzfeldt-Jakob disease with D178N and Met129Val

N. Omer, E. Kahana, S. Simchoni, A. Bar-Shira, T. Naiman, A. Orr-Urtreger, B. Aminov, D. Klepikov, N. Giladi, N. Bregman (Tel Aviv, Israel)

Rare Genetic and Metabolic Diseases · Les Muses Terrace, Level 3

1:45pm-3:15pm: Fatal evolution of cutaneous necrosis in a patient treated with subcutaneous apomorphine infusions

C. Marse, J. Benoit, F. Rocher, C. Giordana (Nice, France)

Clinical Trials, Pharmacology and Treatment · Agora 3 West, Level 3

1:45pm-3:15pm: Feasibility and acceptability of a therapist-delivered physical activity coaching intervention for people with premanifest and early stage Huntington’s Disease and Parkinson’s Disease

K. Long Ms, M. Caciula Phd, C. Friel Edd, L. Quinn Edd (New York City, NY, USA)

Physical and Occupational Therapy · Les Muses Terrace, Level 3